REFERENCE
US FDA.FDA Drug Safety Communication: New Boxed Warning and Contraindication for Adcetris (brentuximab vedotin). FDA Drug Safety Newsletter: [3 pages], 13 Jan 2012. Available from: URL: http://www.fda.gov/drugs/drugsafety/ucm287668.htm
Rights and permissions
About this article
Cite this article
The US FDA is informing of two additional cases of progressive multifocal leukoencephalopathy (PML) associated with brentuximab vedotin [Adcetris].*. React. Wkly. 1385, 5 (2012). https://doi.org/10.2165/00128415-201213850-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-201213850-00010